Orexo | Sustainability Performance
Orexo AB is engaged in the development of pharmaceuticals, particularly in the field of addiction treatment and pain management, with a focus on distinct drug delivery technologies.
1995
Sweden
51 - 200 employees
Pharmaceuticals
$25M - 100M in revenue
N/A in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#7452
Overallⓘ#372
in Swedenⓘ#175
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Energy consumptionGovernance
TargetsFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Controversy level
- Orexo's opioid dependence treatment products operate in a pharmaceutical segment with inherent controversy around addiction treatment approaches.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
2-3
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.